Register
FDA OKs First Rifabutin-Based H pylori Therapy Talicia |
News and Updates
eMediNexus Coverage from: 
FDA OKs First Rifabutin-Based H pylori Therapy Talicia
eMediNexus,  05 November 2019
remove_red_eye 506 Views
#Gastroenterology #Infectious Diseases #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved Talicia, the first rifabutin-based treatment for Helicobacter pylori (H pylori) infection in adults, according to a company news release.

Each delayed-release capsule of Talicia contains omeprazole 10 mg (equivalent to 10.3 mg omeprazole magnesium), amoxicillin 250 mg, and rifabutin 12.5 mg… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now